Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial) - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Feb 1;105(3):283-7.
doi: 10.1016/j.amjcard.2009.09.025. Epub 2009 Dec 22.
Affiliations
- PMID: 20102935
- DOI: 10.1016/j.amjcard.2009.09.025
Randomized Controlled Trial
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial)
John C LaRosa et al. Am J Cardiol. 2010.
Abstract
Analyses of randomized clinical trials are usually restricted to examination of time to first event. However, because many patients have multiple events, this approach precludes much potentially useful clinical and economic data. To assess the effect on overall disease burden in the Treating to New Targets (TNT) study, we evaluated the effect of treatment with atorvastatin 80 versus 10 mg in the period after the occurrence of a first cardiovascular event. In TNT, 10,001 patients with stable coronary heart disease received double-blind therapy with atorvastatin 80 or 10 mg and were followed for 4.9 years. Post hoc time-to-event analysis was used to estimate separate hazard ratios for time to any first, second, third, fourth, and fifth recurrent cardiovascular events. During TNT, 3,082 patients had a first recurrent cardiovascular event, with 1,516, 698, 345, and 197 developing second, third, fourth, and fifth recurrent events, respectively. In patients receiving atorvastatin 80 mg, the relative risk of a first recurrent event was significantly decreased compared to those receiving atorvastatin 10 mg. Significant benefit with the 80-mg dose was also observed for second, third, fourth, and fifth recurrent events. Similar findings were recorded in 5,854 patients with type 2 diabetes mellitus and/or metabolic syndrome and in 3,809 patients > or = 65 years of age compared to younger patients. In conclusion, treatment with atorvastatin 80 mg continued to significantly decrease the risk of any cardiovascular event over time compared to atorvastatin 10 mg in patients who had survived previous events. In TNT, analyses limited to the primary end point significantly underestimated the decrease in total cardiovascular disease burden achieved by intensive low-density lipoprotein cholesterol lowering.
Copyright 2010 Elsevier Inc. All rights reserved.
Comment in
- TNT and recurrent cardiovascular events: high-dose statin therapy offers a lot of bang for the buck.
Toth PP. Toth PP. Curr Atheroscler Rep. 2010 Sep;12(5):283-4. doi: 10.1007/s11883-010-0124-5. Curr Atheroscler Rep. 2010. PMID: 20623206 No abstract available.
Similar articles
- Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Deedwania P, et al. Lancet. 2006 Sep 9;368(9539):919-28. doi: 10.1016/S0140-6736(06)69292-1. Lancet. 2006. PMID: 16962881 Clinical Trial. - Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Shah SJ, et al. J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054. J Am Coll Cardiol. 2008. PMID: 18482661 Clinical Trial. - Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review.
Gregson J, Stone GW, Bhatt DL, Packer M, Anker SD, Zeller C, Redfors B, Pocock SJ. Gregson J, et al. J Am Coll Cardiol. 2023 Oct 3;82(14):1445-1463. doi: 10.1016/j.jacc.2023.07.024. J Am Coll Cardiol. 2023. PMID: 37758440 Review.
Cited by
- Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.
Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Szarek M, et al. J Am Heart Assoc. 2022 Jun 7;11(11):e025504. doi: 10.1161/JAHA.122.025504. Epub 2022 May 27. J Am Heart Assoc. 2022. PMID: 35621222 Free PMC article. Clinical Trial. - Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study.
de Vries TI, Westerink J, Bots ML, Asselbergs FW, Smulders YM, Visseren FLJ. de Vries TI, et al. BMJ Open. 2021 Mar 8;11(3):e038881. doi: 10.1136/bmjopen-2020-038881. BMJ Open. 2021. PMID: 34006017 Free PMC article. - Evaluation of high-dose atorvastatin pretreatment influence in patients preconditioning of post coronary artery bypass graft surgery: A prospective triple blind randomized clinical trial.
Bastani M, Khosravi MB, Shafa M, Azemati S, Maghsoodi B, Asadpour E. Bastani M, et al. Ann Card Anaesth. 2021 Apr-Jun;24(2):209-216. doi: 10.4103/aca.ACA_34_19. Ann Card Anaesth. 2021. PMID: 33884978 Free PMC article. Clinical Trial. - Age is just a number: the concept of time to benefit in older adults.
Hellemans L, Mertens B, Hias J, Tournoy J, Van der Linden LR. Hellemans L, et al. Eur J Hosp Pharm. 2023 Mar;30(2):117-119. doi: 10.1136/ejhpharm-2020-002561. Epub 2021 Apr 16. Eur J Hosp Pharm. 2023. PMID: 33863810 Free PMC article. - Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR, Rydén L, Leiter LA, Lakshmanan M, Dyal L, Probstfield JL, Atisso CM, Shaw JE, Conget I, Cushman WC, Lopez-Jaramillo P, Lanas F, Munoz EGC, Pirags V, Pogosova N, Basile J, Sheu WHH, Temelkova-Kurktschiev T, Raubenheimer PJ, Keltai M, Hall S, Pais P, Colhoun HM, Riddle MC, Gerstein HC. Dagenais GR, et al. Cardiovasc Diabetol. 2020 Nov 25;19(1):199. doi: 10.1186/s12933-020-01179-1. Cardiovasc Diabetol. 2020. PMID: 33239067 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical